Health Care [ 3/12 ] | Biotechnology [ 10/73 ]
NASDAQ | Common Stock
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder.
It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders.
In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines.
It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 11, 25 | -0.47 Decreased by -34.29% | -0.44 Decreased by -6.82% |
| Jun 17, 25 | -0.44 Decreased by -76.00% | -0.85 Increased by +48.24% |
| Feb 11, 25 | -0.46 Decreased by -109.09% | -0.52 Increased by +11.54% |
| Nov 7, 24 | -0.42 Increased by +36.36% | -0.39 Decreased by -7.69% |
| Aug 13, 24 | -0.35 Increased by +62.77% | -0.40 Increased by +12.50% |
| Jun 11, 24 | -0.25 Increased by +85.71% | -0.36 Increased by +30.56% |
| Feb 13, 24 | -0.22 Decreased by -340.00% | -0.30 Increased by +26.67% |
| Nov 9, 23 | -0.66 Decreased by -725.00% | -0.68 Increased by +2.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 244.00 K Increased by +190.48% | -15.10 M Decreased by -40.64% | Decreased by -6.19 K% Increased by +51.58% |
| Mar 31, 25 | -15.00 K Decreased by -107.60% | -13.63 M Decreased by -43.20% | Increased by +90.90 K% Increased by +1.98 K% |
| Dec 31, 24 | 234.00 K Decreased by -43.12% | -14.09 M Decreased by -121.88% | Decreased by -6.02 K% Decreased by -290.09% |
| Sep 30, 24 | 183.00 K Decreased by -34.17% | -12.96 M Decreased by -96.74% | Decreased by -7.08 K% Decreased by -198.87% |
| Jun 30, 24 | 84.00 K Decreased by -52.54% | -10.73 M Decreased by -55.48% | Decreased by -12.78 K% Decreased by -227.63% |
| Mar 31, 24 | 197.30 K Increased by +12.36% | -9.52 M Increased by +22.13% | Decreased by -4.83 K% Increased by +30.69% |
| Dec 31, 23 | 411.40 K Increased by +129.06% | -6.35 M Increased by +34.95% | Decreased by -1.54 K% Increased by +71.60% |
| Sep 30, 23 | 278.00 K Increased by +131.15% | -6.59 M Increased by +62.30% | Decreased by -2.37 K% Decreased by -221.02% |